REG - OptiBiotix Health - Notice of AGM

OptiBiotix HealthAnnouncement

11/06/2018 07:05

RNS Number : 8356Q
OptiBiotix Health PLC
11 June 2018
 


OptiBiotix Health plc
("OptiBiotix" or the "Company")
 
Notice of AGM
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the Annual General Meeting will be held on 4 July 2018 at 11am at the offices of Walbrook PR, 4 Lombard St, London EC3V 9HD. 
 
For further information, please contact:
 



OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below














Cairn Financial Advisers LLP (NOMAD)


Tel: 020 7213 0880




Liam Murray / Jo Turner








 
finnCap (Broker)


 
Tel: 020 7220 0500




Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)








Abigail Wayne (Corporate Broking)


















Walbrook PR Ltd


Tel: 020 7933 8780 or optibiotix@walbrookpr.com




Anna Dunphy


Mob: 07876 741 001








 
About OptiBiotix - www.optibiotix.com 
 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 
 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOAFPMITMBBMBMP